China Resources Pharmaceutical : ANNOUNCEMENT RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE THREE MONTHS ENDED 31 MARCH 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF

DONG-E-E-JIAO FOR THE THREE

MONTHS ENDED 31 MARCH 2021

On 14 April 2021, Dong-E-E-Jiao released its results estimate for the three months ended 31 March 2021.

Dong-E-E-Jiao Company Limited（東阿阿膠股份有限公司）("Dong-E-E-Jiao") is a company incorporated in the People's Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") and approximately

23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited（華潤東阿阿膠有限公司）. The Group controls an effective interest of approximately 21.96% of Dong-E-E-Jiao and accounted for as a subsidiary of the

Company.

On 14 April 2021, Dong-E-E-Jiao released its results estimate for the three months ended 31 March 2021. In which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the three months ended 31 March 2021 would range from RMB55.48 million to RMB72.13 million, representing an increase between 166% and 186% as compared to the net loss of RMB83.87 million for the same period last year (the "Dong-E-E-JiaoResults Estimate").

1

The change in results was mainly due to:

1. Dong-E-E-Jiaoadheres to the consumer-oriented principle, focuses on customer operation, accelerates digital transformation and establishes new growth logic. It will gradually enhance its organizational capabilities, steadily promote innovation in respect of technologies, products and marketing as well as re-branding in order to continuously create value for consumers' health.
2. In the future, Dong-E-E-Jiao will pursue customer growth and retention, achieve incremental expansion and brand building, consolidate the leading position of core products in the market, and facilitate healthy growth in the market. Meanwhile, it will secure its leading status in the Chinese-style nourishing health sector, unleash the brand productivity, and deliver convenient, young and chic product experiences and services to our consumers.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of financial data, those to be disclosed in the quarterly report for the three months ended 31 March 2021 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By order of the Board

China Resources Pharmaceutical Group Limited

Wang Chuncheng

Chairman

Nanchang, 15 April 2021

As at the date of this announcement, the Board comprises Mr. Wang Chuncheng as chairman and non-executive Director, Mr. Han Yuewei, Mr. Li Xiangming and Mdm. Weng Jingwen as executive Directors, Mr. Yu Zhongliang, Mdm. Guo Wei, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.

2